Biotheus is a biotech company specializing in the discovery and development of antibody-based therapeutics to target and neutralize specific disease-causing agents. Their approach aims to enhance treatment efficacy and safety for patients suffering from various conditions, including cancer and autoimmune disorders.

Cullgen develops targeted protein degraders using proprietary E3 ligands to address diseases that currently lack effective therapies, such as certain cancers. Their technology enables the degradation of previously undruggable proteins, offering a new approach to drug discovery and development.

Immusoft utilizes Immune System Programming (ISP™) to reprogram a patient's B cells into plasma cells that produce therapeutic proteins, effectively creating personalized biofactories for treatment. This technology addresses the need for sustained delivery of gene-encoded medicines for rare diseases, offering long-term therapeutic benefits from the patient's own cells.

Inmagene is developing differentiated therapies for immunological and inflammatory diseases using its proprietary QuadraTek® platform, which optimizes safety and efficacy. The company targets conditions such as atopic dermatitis and alopecia areata by inhibiting the OX40/OX40L signaling pathway to improve patient outcomes.

Lysoway Therapeutics utilizes advanced screening methods to identify and develop potent modulators of lysosomal ion channels, which are critical for cellular waste management and metabolism. This technology aims to enhance therapeutic options for diseases linked to lysosomal dysfunction, improving patient outcomes in conditions such as lysosomal storage disorders.

Medilink Therapeutics develops next-generation antibody-drug conjugates (ADCs) that enhance the precision of cancer therapies by targeting tumor cells while minimizing damage to healthy tissue. Their technology addresses the limitations of traditional chemotherapy by improving treatment efficacy and expanding therapeutic windows for patients with unmet clinical needs.

Merck is a research‑intensive biopharmaceutical company that discovers, develops, and manufactures prescription medicines and vaccines across oncology, infectious disease, cardiovascular, immunology, neuroscience, and ophthalmology. It leverages AI‑driven target identification, translational medicine platforms, and a global clinical‑trial network to accelerate development, while its GMP manufacturing capacity and patient‑access programs support large‑scale distribution and affordability.

Rgenta Therapeutics develops oral, small-molecule RNA-targeting medicines aimed at treating previously incurable oncology and neurological disorders. By focusing on RNA regulation, the company addresses the challenge of drugging targets that have been difficult to reach with traditional therapies.

Singular Genomics offers the G4X platform, an ultra high-throughput spatial sequencing technology that enables integrated multiomic analysis of FFPE samples at subcellular resolution. This platform provides researchers with rapid, scalable insights into RNA, protein, and histological data, facilitating advanced discoveries in genomics and medicine.

Yuwell Medical supplies certified medical devices—including patient monitors, ECG machines, infusion pumps, and respiratory support equipment—for hospitals, clinics, and home‑care providers. Its products feature built‑in connectivity to hospital information systems via HL7/DICOM, user‑friendly touchscreen interfaces, and secure cloud‑based remote diagnostics. Yuwell also offers integrated software for real‑time vital sign aggregation and comprehensive after‑sales support, including installation, training, and maintenance.

Zentalis is a clinical-stage biopharmaceutical company developing small molecule therapeutics that target key biological pathways in cancer, specifically utilizing WEE1 inhibition to treat various malignancies. Their therapies aim to improve outcomes for patients with platinum-resistant ovarian cancer and other solid tumors, addressing the need for effective treatment options in challenging cancer types.